NB-PP_1170x120

Boehringer Ingelheim

Praxbind, specific reversal agent for Pradaxa, available nationwide

Praxbind, specific reversal agent for Pradaxa, available nationwide

RIDGEFIELD, Conn. — Boehringer Ingelheim announced that Praxbind (idarucizumab), a specific reversal agent for Pradaxa (dabigatran etexilate mesylate), is now stocked in 3,200 hospitals in all 50 states. This represents a significant increase in the availability of Praxbind since March 2016, when it was stocked in 2,200 institutions. Healthcare providers and patients can quickly search

Study to probe Jardiance effects on kidney disease

Study to probe Jardiance effects on kidney disease

RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Co.  yesterday announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical

Boehringer Ingelheim names Baiker as new U.S. president

Boehringer Ingelheim names Baiker as new U.S. president

RIDGEFIELD, Conn.– Boehringer Ingelheim announced that its U.S. president and chief executive officer Paul Fonteyne will retire and Wolfgang Baiker has been appointed to succeed him, effective March 1. The position will be based at the pharmaceutical company’s U.S. headquarters in Ridgefield. “I am thrilled to return to the U.S. to lead this organization and

Jardiance approved to cut cardiovascular death risk

Jardiance approved to cut cardiovascular death risk

RIDGEFIELD, Conn., and INDIANAPOLIS — Jardiance tablets, marketed by Boehringer Ingelheim and Eli Lilly and Co., have been approved by the Food and Drug Administration to cut the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. BI and Lilly said the FDA clearance makes Jardiance (empagliflozin) the first type

Sanofi names Main to lead new consumer health unit

Sanofi names Main to lead new consumer health unit

PARIS — Sanofi has appointed former Bayer executive Alan Main as executive vice president of its newly formed Consumer HealthCare global business unit. Sanofi said Friday that Main, who also joins its executive committee, will be responsible for building and maintaining the company’s position in the consumer health care market, including the expected integration of

BI rolls out Spiriva Respimat asthma inhaler to pharmacies

BI rolls out Spiriva Respimat asthma inhaler to pharmacies

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals Inc. has released Spiriva Respimat, an asthma treatment, to U.S. pharmacies. BI noted that Spiriva Respimat isn’t a medication for sudden asthma symptoms. The Food and Drug Administration approved a once-daily dose of Spiriva Respimat 2.5 µg (delivered in two puffs of 1.25 µg each) for the long-term maintenance

Sanofi, Boehringer Ingelheim mull business swap

Sanofi, Boehringer Ingelheim mull business swap

NEW YORK — Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.45 billion U.S.), and Boehringer Ingelheim’s consumer health care business,valued at €6.7 billion ($7.32 billion U.S.).

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. have received approval from the Food and Drug Administration for Synjardy tablets, a medication for type 2 diabetes. The companies said Thursday that Synjardy (empagliflozin and metformin hydrochloride) marks their third product containing empagliflozin to be approved by the FDA, following

Hikma to buy Roxane for $2.65 billion

Hikma to buy Roxane for $2.65 billion

LONDON — Hikma Pharmaceuticals PLC, a fast growing multinational pharmaceutical group, plans to acquire Roxane Laboratories from Boehringer Ingelheim in a deal valued at $2.65 billion. Hikma said the agreement stands to transform its position in the U.S. generic drug market, establishing the company as the sixth-largest generics maker by revenue. The addition of Roxane

Boehringer Ingelheim COPD treatment gets FDA approval

Boehringer Ingelheim COPD treatment gets FDA approval

RIDGEFIELD, Conn. — Boehringer Ingelheim has received approval from the Food and Drug Administration for Stiolto Respimat Inhalation Spray, a medication for chronic obstructive pulmonary disease (COPD). The company said Tuesday that Stiolto Respimat Inhalation Spray (tiotropium bromide and olodaterol) was approved as a long-term, once-daily maintenance treatment for airflow obstruction in patients with COPD,